Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements.
Chinese interdisciplinary experts
Consensus
Hepatocellular carcinoma
Molecular targeted therapy
Journal
Liver cancer
ISSN: 2235-1795
Titre abrégé: Liver Cancer
Pays: Switzerland
ID NLM: 101597993
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
15
09
2021
accepted:
15
12
2021
entrez:
11
8
2022
pubmed:
12
8
2022
medline:
12
8
2022
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and causes many cancer-related deaths worldwide; in China, it is the second most prevalent cause of cancer deaths. Most patients are diagnosed clinically with advanced stage disease. For more than a decade, sorafenib, a small-molecular-weight tyrosine kinase inhibitor (SMW-TKI) was the only molecular targeted drug available with a survival benefit for the treatment of advanced HCC. With the development of novel TKIs and immune checkpoint inhibitors for advanced HCC, the management of patients has been greatly improved. However, though angiogenic-based targeted therapy remains the backbone for the systemic treatment of HCC, to date, no Chinese guidelines for novel molecular targeted therapies to treat advanced HCC have been established. Our interdisciplinary panel on the treatment of advanced HCC comprising hepatologists, hepatobiliary surgeons, oncologists, radiologists, pathologists, orthopedic surgeons, traditional Chinese medicine physicians, and interventional radiologists has reviewed the literature in order to develop updated treatment regimens. Panel consensus statements for the appropriate use of new molecular -targeted drugs including doses, combination therapies, adverse reaction management as well as efficacy evaluation, and predictions for treatment of advanced HCC with evidence levels based on published data are presented, thereby providing an overview of molecular targeted therapies for healthcare professionals.
Sections du résumé
Background
UNASSIGNED
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and causes many cancer-related deaths worldwide; in China, it is the second most prevalent cause of cancer deaths. Most patients are diagnosed clinically with advanced stage disease.
Summary
UNASSIGNED
For more than a decade, sorafenib, a small-molecular-weight tyrosine kinase inhibitor (SMW-TKI) was the only molecular targeted drug available with a survival benefit for the treatment of advanced HCC. With the development of novel TKIs and immune checkpoint inhibitors for advanced HCC, the management of patients has been greatly improved. However, though angiogenic-based targeted therapy remains the backbone for the systemic treatment of HCC, to date, no Chinese guidelines for novel molecular targeted therapies to treat advanced HCC have been established. Our interdisciplinary panel on the treatment of advanced HCC comprising hepatologists, hepatobiliary surgeons, oncologists, radiologists, pathologists, orthopedic surgeons, traditional Chinese medicine physicians, and interventional radiologists has reviewed the literature in order to develop updated treatment regimens.
Key Messages
UNASSIGNED
Panel consensus statements for the appropriate use of new molecular -targeted drugs including doses, combination therapies, adverse reaction management as well as efficacy evaluation, and predictions for treatment of advanced HCC with evidence levels based on published data are presented, thereby providing an overview of molecular targeted therapies for healthcare professionals.
Identifiants
pubmed: 35949289
doi: 10.1159/000521596
pii: lic-0011-0192
pmc: PMC9218612
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
192-208Informations de copyright
Copyright © 2022 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
Jia Fan is an editorial board member of Liver Cancer. The remaining authors have no conflicts of interest to declare.
Références
J Hepatol. 2017 Nov;67(5):999-1008
pubmed: 28687477
Front Oncol. 2019 Oct 15;9:1065
pubmed: 31681599
Onco Targets Ther. 2012;5:457-62
pubmed: 23277740
Cancer Chemother Pharmacol. 2017 Nov;80(5):945-954
pubmed: 28932966
Radiology. 2014 Jul;272(1):284-93
pubmed: 24708192
Int J Clin Oncol. 2015 Oct;20(5):952-9
pubmed: 25712158
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Signal Transduct Target Ther. 2020 Aug 11;5(1):146
pubmed: 32782275
Clin Cancer Res. 2021 Feb 15;27(4):1003-1011
pubmed: 33087333
Gut. 2020 Aug;69(8):1492-1501
pubmed: 31801872
Prog Transplant. 2016 Dec;26(4):348-355
pubmed: 27555074
Hepatol Int. 2021 Jun;15(3):621-629
pubmed: 33826043
Oncotarget. 2016 Jul 26;7(30):48586-48599
pubmed: 27191894
Int J Radiat Oncol Biol Phys. 2020 May 1;107(1):106-115
pubmed: 32084526
PLoS One. 2015 Jul 31;10(7):e0133488
pubmed: 26230853
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Evid Based Complement Alternat Med. 2017;2017:3970601
pubmed: 28845183
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255
pubmed: 30285213
Drugs Real World Outcomes. 2020 Jun;7(2):141-149
pubmed: 32048238
Support Care Cancer. 2018 Feb;26(2):415-425
pubmed: 29128952
HPB (Oxford). 2019 Dec;21(12):1687-1696
pubmed: 31153833
Lancet Oncol. 2015 Oct;16(13):1344-54
pubmed: 26361969
BMC Cancer. 2012 Jun 21;12:263
pubmed: 22721173
BMC Cancer. 2021 Feb 28;21(1):206
pubmed: 33639888
J Transplant. 2014;2014:913634
pubmed: 24818010
Liver Cancer. 2020 Jan;9(1):93-104
pubmed: 32071913
World J Gastroenterol. 2018 Sep 28;24(36):4152-4163
pubmed: 30271080
Mol Clin Oncol. 2019 Nov;11(5):447-454
pubmed: 31602300
J Natl Cancer Inst. 2013 Aug 21;105(16):1230-8
pubmed: 23853057
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Anticancer Res. 2019 Sep;39(9):5149-5156
pubmed: 31519627
J Hepatol. 2016 May;64(5):1090-1098
pubmed: 26809111
Cancer Chemother Pharmacol. 2012 Mar;69(3):773-80
pubmed: 22033636
Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575
pubmed: 28648803
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Liver Cancer. 2020 Jan;9(1):28-40
pubmed: 32071907
Liver Transpl. 2018 Jul;24(7):932-945
pubmed: 29710388
Hepatology. 2021 Nov;74(5):2544-2560
pubmed: 34036623
Liver Cancer. 2015 Mar;4(2):115-25
pubmed: 26020033
Arch Med Sci. 2017 Oct;13(6):1383-1393
pubmed: 29181069
Am J Transplant. 2019 Nov;19(11):3176-3184
pubmed: 31365177
World J Gastroenterol. 2015 Oct 21;21(39):11185-98
pubmed: 26494973
Asia Pac J Clin Oncol. 2014 Sep;10(3):255-60
pubmed: 24810940
JAMA. 2010 Nov 17;304(19):2154-60
pubmed: 21081728
Clin Cancer Res. 2019 Jan 15;25(2):515-523
pubmed: 30348638
J Korean Med Sci. 2018 Oct 12;33(45):e283
pubmed: 30402048
Zhonghua Zhong Liu Za Zhi. 2019 Jan 23;41(1):19-28
pubmed: 30678413
Oncol Lett. 2017 Feb;13(2):984-992
pubmed: 28356989
PLoS One. 2020 Apr 20;15(4):e0231828
pubmed: 32310967
J Clin Gastroenterol. 2019 Aug;53(7):486-494
pubmed: 30939505
Cancers (Basel). 2020 Jul 11;12(7):
pubmed: 32664489
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
J Clin Oncol. 2015 Feb 20;33(6):559-66
pubmed: 25547503
J Clin Oncol. 2020 Sep 10;38(26):2960-2970
pubmed: 32716739
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432
pubmed: 29631810
Ann Transl Med. 2020 Dec;8(24):1700
pubmed: 33490212
Ther Adv Med Oncol. 2020 May 20;12:1758835920922051
pubmed: 32547646
Cancers (Basel). 2019 Oct 09;11(10):
pubmed: 31601010
Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1041-7
pubmed: 24661657
Eur J Gastroenterol Hepatol. 2019 Sep;31(9):1148-1156
pubmed: 31247632
Cancer Med. 2018 Sep;7(9):4570-4583
pubmed: 30109780
Oncotarget. 2016 Feb 9;7(6):6639-48
pubmed: 26735891
Radiology. 2013 Nov;269(2):603-11
pubmed: 23864102
Cancer Manag Res. 2019 Nov 26;11:9939-9950
pubmed: 32063720
J Hepatol. 2013 Jun;58(6):1181-7
pubmed: 23395691
Proc (Bayl Univ Med Cent). 2008 Jul;21(3):266-80
pubmed: 18628926
Clin Transplant. 2013 Jul-Aug;27(4):555-61
pubmed: 23758296
Invest New Drugs. 2019 Jun;37(3):567-572
pubmed: 30523474
Hepatol Res. 2014 May;44(5):523-31
pubmed: 23672310
Expert Rev Gastroenterol Hepatol. 2018 Jan;12(1):1-8
pubmed: 28847184
Lancet Oncol. 2021 Jul;22(7):977-990
pubmed: 34143971
Transplantation. 2020 Mar;104(3):568-574
pubmed: 31517781
Oncotarget. 2017 Apr 25;8(17):29416-29427
pubmed: 28177886
Ann Surg. 2008 Nov;248(5):857-62
pubmed: 18948815
Sci Rep. 2015 Mar 30;5:9384
pubmed: 25819872
Ann Oncol. 2016 Nov;27(11):2090-2096
pubmed: 27573564
Cancer Manag Res. 2019 Nov 01;11:9321-9330
pubmed: 31802950
Lancet Oncol. 2019 Aug;20(8):1070-1082
pubmed: 31262657
Cancers (Basel). 2020 Jan 26;12(2):
pubmed: 31991869